Globalpharma, UAE’s leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, unveiled its ambitious plans for 2025, marked by the launch of 25 innovative products across key therapeutic areas.
The areas include diabetes, cardiovascular, gastroenterology, and orthopaedics.
This milestone reflects Globalpharma’s commitment to delivering high-quality, accessible medications that address the region’s evolving healthcare needs, the company said.
“Globalpharma’s growth and innovation perfectly align with Dubai Investments’ vision of driving transformation in key industries,” said Mohammed Saeed Al Raqbani, General Manager, Dubai Investments Industries & Masharie and Board Director of Globalpharma.
“As the pharmaceutical sector continues to grow, the Group is strategically positioning Globalpharma to capitalize on emerging opportunities,” he said.
Al Raqbani said the goal is to not only contribute to the healthcare ecosystem in the region, but also to establish Dubai Investments as a significant player in the global pharmaceutical landscape.
“Through innovation, partnerships, and a focus on patient-centric solutions, we are confident that Globalpharma will continue to elevate its presence and create meaningful impact,” he said.
As part of Globalpharma’s broader expansion efforts, the company is strengthening its distribution network and forging new partnerships.
Additionally, Globalpharma said it is refining its market entry strategies to adapt to the unique requirements of regional markets, solidifying its presence in key territories while exploring new opportunities.
“Our strategic focus in 2025 revolves around innovation, accessibility, and partnerships,” said Basem Albarahmeh, General Manager, Globalpharma.
Follow us on
